Shots:

• The P-II study evaluates Herzuma (a trastuzumab biosimilar) + gedatolisib in patients with HER2–positive mBC with a PIK3CA aberration whose cancers had progressed after multiple lines of therapy
• The results showed a 58.8% ORR with manageable toxicity, DCR was 82.4%, m-PFS was 5.9mos. Additionally, 3 patients had progressive disease, 4 with SD, and 10 showed PR. The results were presented at SABCS 2021
• Trastuzumab is a mAb that targets HER2 & binds to the HER2/neu receptor and reduces HER2 expression along with the growth of blood vessels to support tumor growth while Gedatolisib targets the mTOR/PIK3 signaling pathway

Ref: Center for Biosimilars | Image: Celltrion